[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100659666":3},{"organization":4,"outcomesModule":7,"designInfo":35,"detailedDescription":11,"studyPopulation":11,"armGroups":41,"interventions":54,"overallOfficials":68,"centralContacts":72,"locations":81,"responsibleParty":101,"collaborators":11,"id":103,"slug":104,"hasResults":105,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":11,"eligibilityCriteria":109,"healthyVolunteers":110,"sex":111,"minAge":112,"maxAge":113,"enrollmentInfo":114,"targetDuration":11,"studyType":117,"phases":118,"briefSummary":120,"conditions":121,"keywords":11,"overallStatus":123,"whyStopped":11,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":133},{"fullName":5,"class":6},"Eli Lilly and Company","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":17,"otherOutcomes":11},[9,13,15],{"measure":10,"description":11,"timeFrame":12},"Part 1: Urinary Excretion of [¹⁴C]-LY4515100 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered",null,"Predose Up to Day 14",{"measure":14,"description":11,"timeFrame":12},"Part 1: Fecal Excretion of [¹⁴C]-LY4515100 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered",{"measure":16,"description":11,"timeFrame":12},"Part 2: Dose Normalized Ratio of the Area Under the Concentration-Time Curve After Oral Administration (AUCpo) to Area Under the Concentration-Time Curve After Intravenous Administration (AUCiv) of LY4515100",[18,20,22,24,26,29,31,33],{"measure":19,"description":11,"timeFrame":12},"Part 1: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve from Time Zero to Infinity (AUC[0-inf]) of Total Plasma Radioactivity",{"measure":21,"description":11,"timeFrame":12},"Part 1: PK: Maximum Concentration (Cmax) of Total Plasma Radioactivity",{"measure":23,"description":11,"timeFrame":12},"Part 1: Total Radioactivity Recovered in Urine, Feces, and Expired Air",{"measure":25,"description":11,"timeFrame":12},"Part 1: Total Number of Metabolites of LY4515100 in Urine, Feces, and Plasma",{"measure":27,"description":11,"timeFrame":28},"Part 2: PK: Area Under the Concentration Versus Time Curve from Time Zero to Infinity (AUC[0-inf]) of [¹⁴C]-LY4515100","Predose Up to Day 9",{"measure":30,"description":11,"timeFrame":28},"Part 2: PK: Maximum Concentration (Cmax) of [¹⁴C]-LY4515100",{"measure":32,"description":11,"timeFrame":28},"Part 2: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve from Time Zero to Infinity (AUC[0-inf]) of Total Plasma Radioactivity",{"measure":34,"description":11,"timeFrame":28},"Part 2: PK: Maximum Concentration (Cmax) of Total Plasma Radioactivity",{"allocation":36,"interventionModel":37,"interventionModelDescription":11,"primaryPurpose":38,"observationalModel":11,"timePerspective":11,"maskingInfo":39},"NON_RANDOMIZED","PARALLEL","BASIC_SCIENCE",{"masking":40,"maskingDescription":11,"whoMasked":11},"NONE",[42,48],{"label":43,"type":44,"description":45,"interventionNames":46},"[¹⁴C]-LY4515100 Part 1","EXPERIMENTAL","\\[¹⁴C\\]-LY4515100 containing radioactivity administered orally",[47],"Drug: [¹⁴C]-LY4515100 Oral Solution",{"label":49,"type":44,"description":50,"interventionNames":51},"LY4515100 + [¹⁴C]-LY4515100 Part 2","LY4515100 administered orally with \\[¹⁴C\\]-LY4515100 containing radioactivity administered intravenously (IV)",[52,53],"Drug: LY4515100 Tablet","Drug: [¹⁴C]-LY4515100 IV",[55,60,64],{"type":56,"name":57,"description":58,"armGroupLabels":59,"otherNames":11},"DRUG","[¹⁴C]-LY4515100 Oral Solution","\\[¹⁴C\\]-LY4515100 administered orally",[43],{"type":56,"name":61,"description":62,"armGroupLabels":63,"otherNames":11},"LY4515100 Tablet","LY4515100 administered orally",[49],{"type":56,"name":65,"description":66,"armGroupLabels":67,"otherNames":11},"[¹⁴C]-LY4515100 IV","\\[¹⁴C\\]-LY4515100 administered IV",[49],[69],{"name":70,"affiliation":5,"role":71},"Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC\u002FGMT - 5 hours, EST)","STUDY_DIRECTOR",[73,78],{"name":74,"role":75,"phone":76,"phoneExt":11,"email":77},"Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or","CONTACT","1-317-615-4559","LillyTrials@Lilly.com",{"name":79,"role":75,"phone":11,"phoneExt":11,"email":80},"Physicians interested in becoming principal investigators please contact","clinical_inquiry_hub@lilly.com",[82],{"facility":83,"status":11,"city":84,"state":85,"zip":86,"country":87,"countryCode":88,"cosmosGeoPoint":89,"geoPoint":94,"contacts":95},"Fortrea Clinical Research Unit","Madison","Wisconsin","53704","United States","US",{"type":90,"coordinates":91},"Point",[92,93],-89.40123,43.07305,{"lat":93,"lon":92},[96,98],{"name":11,"role":75,"phone":97,"phoneExt":11,"email":11},"608-442-8200",{"name":99,"role":100,"phone":11,"phoneExt":11,"email":11},"Kimberly Cruz","PRINCIPAL_INVESTIGATOR",{"type":102,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100659666","phase-1-a-study-of-ly4515100-in-healthy-male-participants-100659666",false,"NCT07867327","A Study of LY4515100 in Healthy Male Participants","A Phase 1, Open-Label, 2-Part Study of the Absorption, Metabolism, Excretion, and Bioavailability of [¹⁴C]-LY4515100 in Healthy Male Participants","Inclusion Criteria:\n\n* Are overtly healthy as determined by medical evaluation.\n* Have a body mass index (BMI) within the range of 18.0 to 35.0 kilograms per square meter (kg\u002Fm²), inclusive.\n\nExclusion Criteria:\n\n* Have significant previous or current history of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrinal, hematological, neurological, thromboembolism, or bleeding disorder capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the study intervention; or of interfering with the interpretation of data.\n* Have a significant history of or current psychiatric disorders.\n* Have history of stomach or intestinal surgery or resection that would potentially alter absorption or excretion of orally administered drugs. Uncomplicated appendectomy and hernia repair will be allowed.\n* Have a history of constipation or have had acute constipation within 3 weeks prior to check-in.\n* Have had exposure to significant diagnostic, therapeutic, or employment-related radiation within 12 months prior to dosing, for example, serial x-ray or computed tomography scans, barium meal, or current employment in a job requiring radiation exposure monitoring.",true,"MALE","18 Years","55 Years",{"count":115,"type":116},16,"ESTIMATED","INTERVENTIONAL",[119],"PHASE1","The main purpose of this study is to evaluate how the body handles \\[¹⁴C\\]-LY4515100. The study will investigate how much \\[¹⁴C\\]-LY4515100 enters the bloodstream from the stomach or intestines and is available to have an effect on the body, how the body changes \\[¹⁴C\\]-LY4515100 so that it can be used or removed, and how the body gets rid of \\[¹⁴C\\]-LY4515100. For each participant, the study will last about 9 weeks and will include a Clinical Research Unit (CRU) stay lasting between 10 and 30 days.",[122],"Healthy","NOT_YET_RECRUITING","2026-10-05",{"date":126,"type":127},"2026-10-09","ACTUAL",{"date":129,"type":116},"2026-10",{"date":131,"type":116},"2026-12",{"name":5,"class":6},1]